LDN-209973 | 1233355-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: LDN-209973
• 英文别名: 4-(2,7-Dimethoxyacridin-9-yl)butan-1-amine
• CAS: 1233355-50-4
• 化学式: C₁₉H₂₂N₂O₂
• 分子量: 310.396
• InChiKey: CUZSEXYSGYTADV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,4'-二甲氧基二苯胺 在 palladium on activated charcoal 三乙基硅烷 、 indium(III) chloride 、 selenium(IV) oxide 、 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 LDN-209973
  参考文献：
  名称：

  [EN] ACRIDINES AS INHIBITORS OF HASPIN AND DYRK KINASES
  [FR] ACRIDINES EN TANT QU'INHIBITEURS DES KINASES HASPINE ET DYRK

  摘要：

  公开号：

  WO2011127406A3

文献信息

• Acridines As Inhibitors Of Haspin And DYRK Kinases
  申请人：Higgins Jonathan

  公开号：US20130102627A1

  公开（公告）日：2013-04-25

  The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.

  本公开涉及I式化合物，它们是Haspin激酶和DYRK激酶的抑制剂。本公开的化合物及其组合物在治疗与Haspin激酶和DYRK激酶表达和/或活性相关的疾病方面是有用的。
• Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors
  作者：Gregory D. Cuny、Maxime Robin、Natalia P. Ulyanova、Debasis Patnaik、Valerie Pique、Gilles Casano、Ji-Feng Liu、Xiangjie Lin、Jun Xian、Marcie A. Glicksman、Ross L. Stein、Jonathan M.G. Higgins

  DOI：10.1016/j.bmcl.2010.04.150

  日期：2010.6

  Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly expressed during cell proliferation, including in a number of neoplasms. Consequently, it has emerged as a potential therapeutic target in oncology. A high throughput screen of approximately 140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed that the structure-activity relationship (SAR) of the acridine series for haspin and DYRK2 inhibition had many similarities. However, several structural differences were noted that allowed generation of a potent haspin kinase inhibitor (33, IC(50) <60 nM) with 180fold selectivity over DYRK2. In addition, a moderately potent DYRK2 inhibitor (41, IC(50) <400 nM) with a 5.4-fold selectivity over haspin was also identified. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] ACRIDINES AS INHIBITORS OF HASPIN AND DYRK KINASES<br/>[FR] ACRIDINES EN TANT QU'INHIBITEURS DES KINASES HASPINE ET DYRK
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2011127406A3

  公开（公告）日：2012-01-26